** Brokerage Wells Fargo cuts PT of medical software company Omnicell OMCL.O to $40 from $49; maintains "equal weight" rating
** New PT is a 5.4% downside to the stock's last close
** Brokerage says OMCL is "poised to offer 2025 Product revenue guidance below consensus when it reports its 4Q24 results"
** Brokerage lowers 2025 product revenue forecast to $596 mln from $643 mln
** Brokerage says XT Extend offsetting low backlog coverage in 2025 "doesn't seem likely"
** OMCL's XT Extend is a healthcare tech upgrade for better security and user experience
** Brokerage says OMCL's decision to exit its Medimat Dispensing product line could drive "margin accretion" in 2025
** OMCL gained 19.2% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))